Consumer healthcare mega merger: Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion cash and stock deal; $1.9 billion cost savings targeted post-merger
Consumer healthcare mega merger: Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion cash and stock deal; $1.9 billion cost savings targeted post-merger
Kimberly-Clark is acquiring Tylenol maker Kenvue for approximately $48.7 billion in a cash-and-stock deal, creating a major consumer health goods company. The combined entity is projected to generate $32 billion in annual net revenues and achieve $1.9 billion in cost savings. Kimberly-Clark's CEO Mike Hsu will lead the merged company, which will retain its Texas headquarters.
Kimberly-Clark is acquiring Tylenol maker Kenvue for approximately $48.7 billion in a cash-and-stock deal, creating a major consumer health goods company. The combined entity is projected to generate $32 billion in annual net revenues and achieve $1.9 billion in cost savings. Kimberly-Clark's CEO Mike Hsu will lead the merged company, which will retain its Texas headquarters.
Kimberly-Clark is acquiring Tylenol maker Kenvue for approximately $48.7 billion in a cash-and-stock deal, creating a major consumer health goods company. The combined entity is projected to generate $32 billion in annual net revenues and achieve $1.9 billion in cost savings. Kimberly-Clark's CEO Mike Hsu will lead the merged company, which will retain its Texas headquarters. 
